This article is part of the supplement: Proceedings of the 11th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI): Basic, Epidemiologic, and Clinical Research
Poster presentation
Pathology of rituximab-induced Kaposi sarcoma flare: role of B-cell depletion
1 Department of Pathology, Baystate Medical Center, Tufts University School of Medicine, Springfield, Massachusetts, USA
2 Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, USA
3 Virginia Mason Medical Center, Seattle, Washington, USA
4 Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
Infectious Agents and Cancer 2009, 4(Suppl 2):P33 doi:10.1186/1750-9378-4-S2-P33
Published: 17 June 2009First paragraph (this article has no abstract)
Kaposi sarcoma (KS) flare (exacerbation) may occur following therapy with corticosteroids, as part of the immune reconstitution inflammatory syndrome seen with highly active antiretroviral therapy (HAART), and after rituximab therapy. The exact mechanism responsible for iatrogenic KS flare is unclear. Therefore, the aim of this study was to investigate the pathologic features in cases of AIDS-associated KS flare.